{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:10:06Z","timestamp":1773184206146,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer-specific promoter driven replication of oncolytic adenovirus (Ad) is cancer-specific, but shows low transcriptional activity. Thus, we generated several chimeric \u03b1-fetoprotein (AFP) promoter variants, containing reconstituted enhancer and silencer regions, to preferentially drive Ad replication in hepatocellular carcinoma (HCC). Modified AFP promoter, containing 2 enhancer A regions and a single enhancer B region (a2bm), showed strong and HCC-specific transcription. In AFP-positive HCCs, gene expression was 43- to 456-fold higher than those of control AFP promoter lacking enhancers. a2bm promoter was further modified by inserting multiple hypoxia-responsive elements (HRE) to generate Ha2bm promoter, which showed stronger transcriptional activity than a2bm promoter under hypoxic conditions. Ha2bm promoter-regulated oncolytic Ad (Ha2bm-d19) showed a stronger antitumor and proapoptotic effect than did a2bm promoter-regulated oncolytic Ad (a2bm-d19) in HCC xenograft tumors. Systemically administered Ha2bm-d19 caused no observable hepatotoxicity, whereas control replication-competent Ad, lacking cancer specificity (d19), induced significant hepatic damage. Ha2bm-d19 caused significantly lower expression of interleukin-6 than d19, showing that HCC-targeted delivery of Ad attenuates induction of the innate immune response against Ad. This chimeric AFP promoter enabled Ad to overcome the hypoxic tumor microenvironment and target HCC with high specificity, rendering it a promising candidate for the treatment of aggressive HCCs.<\/jats:p>","DOI":"10.1038\/s41598-018-20268-6","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T11:57:17Z","timestamp":1517227037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions"],"prefix":"10.1038","volume":"8","author":[{"given":"A-Rum","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinWoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"20268_CR1","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams, S. et al. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32, 2959\u2013+, https:\/\/doi.org\/10.1200\/Jco.2013.55.0491 (2014).","journal-title":"J Clin Oncol"},{"key":"20268_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","volume":"127","author":"FX Bosch","year":"2004","unstructured":"Bosch, F. X., Ribes, J., Diaz, M. & Cleries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5\u2013S16 (2004).","journal-title":"Gastroenterology"},{"key":"20268_CR3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet, J. M., Burroughs, A. & Bruix, J. Hepatocellular carcinoma. Lancet 362, 1907\u20131917, https:\/\/doi.org\/10.1016\/S0140-6736(03)14964-1 (2003).","journal-title":"Lancet"},{"key":"20268_CR4","doi-asserted-by":"crossref","first-page":"11121","DOI":"10.18632\/oncotarget.2553","volume":"5","author":"PY Zhuang","year":"2014","unstructured":"Zhuang, P. Y. et al. Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy. Oncotarget 5, 11121\u201311132 (2014).","journal-title":"Oncotarget"},{"key":"20268_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1517\/14712598.1.3.525","volume":"1","author":"D Kirn","year":"2001","unstructured":"Kirn, D. Oncolytic virotherapy for cancer with the adenovirusdl1520 (Onyx-015): results of phase I and II trials. Expert opinion on biological therapy 1, 525\u2013538, https:\/\/doi.org\/10.1517\/14712598.1.3.525 (2001).","journal-title":"Expert opinion on biological therapy"},{"key":"20268_CR6","first-page":"798","volume":"6","author":"I Ganly","year":"2000","unstructured":"Ganly, I. et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 6, 798\u2013806 (2000).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"20268_CR7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/104303403766682205","volume":"14","author":"DE Post","year":"2003","unstructured":"Post, D. E., Khuri, F. R., Simons, J. W. & Van Meir, E. G. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 14, 933\u2013946, https:\/\/doi.org\/10.1089\/104303403766682205 (2003).","journal-title":"Hum Gene Ther"},{"key":"20268_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/sj.cgt.7700771","volume":"12","author":"B Everts","year":"2005","unstructured":"Everts, B. & van der Poel, H. G. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12, 141\u2013161 (2005).","journal-title":"Cancer Gene Ther"},{"key":"20268_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","volume":"81","author":"RA Weinberg","year":"1995","unstructured":"Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 81, 323\u2013330 (1995).","journal-title":"Cell"},{"key":"20268_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1089\/104303403769211637","volume":"14","author":"E Kim","year":"2003","unstructured":"Kim, E. et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 14, 1415\u20131428, https:\/\/doi.org\/10.1089\/104303403769211637 (2003).","journal-title":"Hum Gene Ther"},{"key":"20268_CR11","first-page":"4663","volume":"62","author":"DM Nettelbeck","year":"2002","unstructured":"Nettelbeck, D. M., Rivera, A. A., Balague, C., Alemany, R. & Curiel, D. T. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer\/promoter. Cancer research 62, 4663\u20134670 (2002).","journal-title":"Cancer research"},{"key":"20268_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2174\/156652309789753356","volume":"9","author":"H Jiang","year":"2009","unstructured":"Jiang, H., Gomez-Manzano, C., Lang, F. F., Alemany, R. & Fueyo, J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Current gene therapy 9, 422\u2013427 (2009).","journal-title":"Current gene therapy"},{"key":"20268_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/978-1-59745-561-9_35","volume":"542","author":"M Opyrchal","year":"2009","unstructured":"Opyrchal, M., Aderca, I. & Galanis, E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods in molecular biology 542, 705\u2013717, https:\/\/doi.org\/10.1007\/978-1-59745-561-9_35 (2009).","journal-title":"Methods in molecular biology"},{"key":"20268_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/sj.cgt.7700494","volume":"9","author":"J Kim","year":"2002","unstructured":"Kim, J., Cho, J. Y., Kim, J. H., Jung, K. C. & Yun, C. O. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer gene therapy 9, 725\u2013736, https:\/\/doi.org\/10.1038\/sj.cgt.7700494 (2002).","journal-title":"Cancer gene therapy"},{"key":"20268_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2016.10.006","volume":"463","author":"C Sauzay","year":"2016","unstructured":"Sauzay, C. et al. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clinica chimica acta; international journal of clinical chemistry 463, 39\u201344, https:\/\/doi.org\/10.1016\/j.cca.2016.10.006 (2016).","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"key":"20268_CR16","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1128\/MCB.11.12.5885","volume":"11","author":"H Nakabayashi","year":"1991","unstructured":"Nakabayashi, H. et al. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Molecular and cellular biology 11, 5885\u20135893 (1991).","journal-title":"Molecular and cellular biology"},{"key":"20268_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0378-1119(90)90091-5","volume":"91","author":"DW Kim","year":"1990","unstructured":"Kim, D. W., Uetsuki, T., Kaziro, Y., Yamaguchi, N. & Sugano, S. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 91, 217\u2013223 (1990).","journal-title":"Gene"},{"key":"20268_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","volume":"108","author":"H Niwa","year":"1991","unstructured":"Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193\u2013199 (1991).","journal-title":"Gene"},{"key":"20268_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1006\/bbrc.1997.8087","volume":"244","author":"Y Sato","year":"1998","unstructured":"Sato, Y. et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochemical and biophysical research communications 244, 455\u2013462, https:\/\/doi.org\/10.1006\/bbrc.1997.8087 (1998).","journal-title":"Biochemical and biophysical research communications"},{"key":"20268_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/mt.2013.93","volume":"21","author":"S Bravo","year":"2013","unstructured":"Bravo, S. et al. Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence. Molecular therapy: the journal of the American Society of Gene Therapy 21, 1403\u20131412, https:\/\/doi.org\/10.1038\/mt.2013.93 (2013).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"20268_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1089\/10430349950017725","volume":"10","author":"PL Hallenbeck","year":"1999","unstructured":"Hallenbeck, P. L. et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 10, 1721\u20131733, https:\/\/doi.org\/10.1089\/10430349950017725 (1999).","journal-title":"Hum Gene Ther"},{"key":"20268_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0304-3835(02)00017-4","volume":"180","author":"J Kim","year":"2002","unstructured":"Kim, J. et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett 180, 23\u201332 (2002).","journal-title":"Cancer Lett"},{"key":"20268_CR23","first-page":"2559","volume":"57","author":"R Rodriguez","year":"1997","unstructured":"Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer research 57, 2559\u20132563 (1997).","journal-title":"Cancer research"},{"key":"20268_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0092-8674(89)90877-5","volume":"59","author":"M Frain","year":"1989","unstructured":"Frain, M. et al. The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 59, 145\u2013157 (1989).","journal-title":"Cell"},{"key":"20268_CR25","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1016\/S0021-9258(18)61269-4","volume":"262","author":"K Watanabe","year":"1987","unstructured":"Watanabe, K., Saito, A. & Tamaoki, T. Cell-specific enhancer activity in a far upstream region of the human alpha-fetoprotein gene. The Journal of biological chemistry 262, 4812\u20134818 (1987).","journal-title":"The Journal of biological chemistry"},{"key":"20268_CR26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.14.1.34","volume":"14","author":"R Ravi","year":"2000","unstructured":"Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes & development 14, 34\u201344 (2000).","journal-title":"Genes & development"},{"key":"20268_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2005.06.038","volume":"77","author":"M Nordsmark","year":"2005","unstructured":"Nordsmark, M. et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 77, 18\u201324, https:\/\/doi.org\/10.1016\/j.radonc.2005.06.038 (2005).","journal-title":"Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"20268_CR28","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.1158\/1078-0432.CCR-06-0480","volume":"12","author":"DJ Brennan","year":"2006","unstructured":"Brennan, D. J. et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clinical cancer research: an official journal of the American Association for Cancer Research 12, 6421\u20136431, https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0480 (2006).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"20268_CR29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/1535-7163.647.3.5","volume":"3","author":"G Powis","year":"2004","unstructured":"Powis, G. & Kirkpatrick, L. Hypoxia inducible factor-1alpha as a cancer drug target. Molecular cancer therapeutics 3, 647\u2013654 (2004).","journal-title":"Molecular cancer therapeutics"},{"key":"20268_CR30","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/sj.gt.3302448","volume":"12","author":"BH Shen","year":"2005","unstructured":"Shen, B. H. & Hermiston, T. W. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene therapy 12, 902\u2013910, https:\/\/doi.org\/10.1038\/sj.gt.3302448 (2005).","journal-title":"Gene therapy"},{"key":"20268_CR31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.gt.3302459","volume":"12","author":"T Pipiya","year":"2005","unstructured":"Pipiya, T. et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene therapy 12, 911\u2013917, https:\/\/doi.org\/10.1038\/sj.gt.3302459 (2005).","journal-title":"Gene therapy"},{"key":"20268_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1756-9966-29-84","volume":"29","author":"XF Fei","year":"2010","unstructured":"Fei, X. F. et al. Development of clinically relevant orthotopic xenograft mouse model of metastatic lung cancer and glioblastoma through surgical tumor tissues injection with trocar. Journal of experimental & clinical cancer research: CR 29, 84, https:\/\/doi.org\/10.1186\/1756-9966-29-84 (2010).","journal-title":"Journal of experimental & clinical cancer research: CR"},{"key":"20268_CR33","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1111\/j.1440-1746.2008.05340.x","volume":"23","author":"N Mitsuhashi","year":"2008","unstructured":"Mitsuhashi, N. et al. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. Journal of gastroenterology and hepatology 23, e189\u2013197, https:\/\/doi.org\/10.1111\/j.1440-1746.2008.05340.x (2008).","journal-title":"Journal of gastroenterology and hepatology"},{"key":"20268_CR34","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1073\/pnas.0711757105","volume":"105","author":"O Kalyuzhniy","year":"2008","unstructured":"Kalyuzhniy, O. et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proceedings of the National Academy of Sciences of the United States of America 105, 5483\u20135488, https:\/\/doi.org\/10.1073\/pnas.0711757105 (2008).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"20268_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","volume":"132","author":"SN Waddington","year":"2008","unstructured":"Waddington, S. N. et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397\u2013409, https:\/\/doi.org\/10.1016\/j.cell.2008.01.016 (2008).","journal-title":"Cell"},{"key":"20268_CR36","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","volume":"108","author":"AL Parker","year":"2006","unstructured":"Parker, A. L. et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554\u20132561, https:\/\/doi.org\/10.1182\/blood-2006-04-008532 (2006).","journal-title":"Blood"},{"key":"20268_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10555-007-9066-y","volume":"26","author":"D Liao","year":"2007","unstructured":"Liao, D. & Johnson, R. S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer metastasis reviews 26, 281\u2013290, https:\/\/doi.org\/10.1007\/s10555-007-9066-y (2007).","journal-title":"Cancer metastasis reviews"},{"key":"20268_CR38","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.neo.2014.07.003","volume":"16","author":"EK Rofstad","year":"2014","unstructured":"Rofstad, E. K., Galappathi, K. & Mathiesen, B. S. Tumor interstitial fluid pressure-a link between tumor hypoxia, microvascular density, and lymph node metastasis. Neoplasia 16, 586\u2013594, https:\/\/doi.org\/10.1016\/j.neo.2014.07.003 (2014).","journal-title":"Neoplasia"},{"key":"20268_CR39","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1128\/MCB.8.12.5179","volume":"8","author":"K Sawadaishi","year":"1988","unstructured":"Sawadaishi, K., Morinaga, T. & Tamaoki, T. Interaction of a hepatoma-specific nuclear factor with transcription-regulatory sequences of the human alpha-fetoprotein and albumin genes. Molecular and cellular biology 8, 5179\u20135187 (1988).","journal-title":"Molecular and cellular biology"},{"key":"20268_CR40","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/1078-0432.CCR-10-0664","volume":"16","author":"OJ Kwon","year":"2010","unstructured":"Kwon, O. J. et al. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research 16, 6071\u20136082, https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-0664 (2010).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"20268_CR41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0021-9258(17)31253-X","volume":"264","author":"H Nakabayashi","year":"1989","unstructured":"Nakabayashi, H. et al. Transcriptional regulation of alpha-fetoprotein expression by dexamethasone in human hepatoma cells. The Journal of biological chemistry 264, 266\u2013271 (1989).","journal-title":"The Journal of biological chemistry"},{"key":"20268_CR42","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/hep.23818","volume":"52","author":"H Xu","year":"2010","unstructured":"Xu, H. et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology (Baltimore, Md.) 52, 1431\u20131442, https:\/\/doi.org\/10.1002\/hep.23818 (2010).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"20268_CR43","doi-asserted-by":"publisher","first-page":"26661","DOI":"10.1074\/jbc.274.38.26661","volume":"274","author":"J Ye","year":"1999","unstructured":"Ye, J. et al. Regulation of a cell type-specific silencer in the human interleukin-3 gene promoter by the transcription factor YY1 and an AP2 sequence-recognizing factor. The Journal of biological chemistry 274, 26661\u201326667 (1999).","journal-title":"The Journal of biological chemistry"},{"key":"20268_CR44","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.tig.2015.07.001","volume":"31","author":"A Feuerborn","year":"2015","unstructured":"Feuerborn, A. & Cook, P. R. Why the activity of a gene depends on its neighbors. Trends in genetics: TIG 31, 483\u2013490, https:\/\/doi.org\/10.1016\/j.tig.2015.07.001 (2015).","journal-title":"Trends in genetics: TIG"},{"key":"20268_CR45","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.4161\/cbt.8.15.8940","volume":"8","author":"ZX Wang","year":"2009","unstructured":"Wang, Z. X., Bian, H. B., Yang, J. S., De, W. & Ji, X. H. Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer. Cancer biology & therapy 8, 1480\u20131488 (2009).","journal-title":"Cancer biology & therapy"},{"key":"20268_CR46","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/mt.2009.103","volume":"17","author":"LL Policastro","year":"2009","unstructured":"Policastro, L. L. et al. Suppression of cancer growth by nonviral gene therapy based on a novel reactive oxygen species-responsive promoter. Molecular therapy: the journal of the American Society of Gene Therapy 17, 1355\u20131364, https:\/\/doi.org\/10.1038\/mt.2009.103 (2009).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"20268_CR47","first-page":"1458","volume":"62","author":"MC Luna","year":"2002","unstructured":"Luna, M. C. et al. Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter. Cancer research 62, 1458\u20131461 (2002).","journal-title":"Cancer research"},{"key":"20268_CR48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V95.1.189","volume":"95","author":"H Kimura","year":"2000","unstructured":"Kimura, H. et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95, 189\u2013197 (2000).","journal-title":"Blood"},{"key":"20268_CR49","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood-2002-06-1693","volume":"101","author":"T Kietzmann","year":"2003","unstructured":"Kietzmann, T., Samoylenko, A., Roth, U. & Jungermann, K. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 101, 907\u2013914, https:\/\/doi.org\/10.1182\/blood-2002-06-1693 (2003).","journal-title":"Blood"},{"key":"20268_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1089-3261(05)70156-2","volume":"5","author":"M Colombo","year":"2001","unstructured":"Colombo, M. Screening for cancer in viral hepatitis. Clinics in liver disease 5, 109\u2013122 (2001).","journal-title":"Clinics in liver disease"},{"key":"20268_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","volume":"33","author":"GL Semenza","year":"2012","unstructured":"Semenza, G. L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends in pharmacological sciences 33, 207\u2013214, https:\/\/doi.org\/10.1016\/j.tips.2012.01.005 (2012).","journal-title":"Trends in pharmacological sciences"},{"key":"20268_CR52","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrc2540","volume":"8","author":"JA Bertout","year":"2008","unstructured":"Bertout, J. A., Patel, S. A. & Simon, M. C. The impact of O2 availability on human cancer. Nature reviews. Cancer 8, 967\u2013975, https:\/\/doi.org\/10.1038\/nrc2540 (2008).","journal-title":"Nature reviews. Cancer"},{"key":"20268_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.niox.2008.04.026","volume":"19","author":"H Yasuda","year":"2008","unstructured":"Yasuda, H. Solid tumor physiology and hypoxia-induced chemo\/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric oxide: biology and chemistry 19, 205\u2013216, https:\/\/doi.org\/10.1016\/j.niox.2008.04.026 (2008).","journal-title":"Nitric oxide: biology and chemistry"},{"key":"20268_CR54","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3892\/mco.2013.119","volume":"1","author":"YJ Zhao","year":"2013","unstructured":"Zhao, Y. J., Ju, Q. & Li, G. C. Tumor markers for hepatocellular carcinoma. Molecular and clinical oncology 1, 593\u2013598, https:\/\/doi.org\/10.3892\/mco.2013.119 (2013).","journal-title":"Molecular and clinical oncology"},{"key":"20268_CR55","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1517\/13543784.2015.1058776","volume":"24","author":"O Waidmann","year":"2015","unstructured":"Waidmann, O. & Trojan, J. Novel drugs in clinical development for hepatocellular carcinoma. Expert opinion on investigational drugs 24, 1075\u20131082, https:\/\/doi.org\/10.1517\/13543784.2015.1058776 (2015).","journal-title":"Expert opinion on investigational drugs"},{"key":"20268_CR56","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/j.1572-0241.1999.01158.x","volume":"94","author":"N Koide","year":"1999","unstructured":"Koide, N. et al. Alpha-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis. The American journal of gastroenterology 94, 1658\u20131663, https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01158.x (1999).","journal-title":"The American journal of gastroenterology"},{"key":"20268_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2016.02.046","volume":"231","author":"AR Yoon","year":"2016","unstructured":"Yoon, A. R. et al. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model. Journal of controlled release: official journal of the Controlled Release Society 231, 2\u201316, https:\/\/doi.org\/10.1016\/j.jconrel.2016.02.046 (2016).","journal-title":"Journal of controlled release: official journal of the Controlled Release Society"},{"key":"20268_CR58","doi-asserted-by":"publisher","first-page":"34875","DOI":"10.18632\/oncotarget.5332","volume":"6","author":"AR Yoon","year":"2015","unstructured":"Yoon, A. R., Hong, J. & Yun, C. O. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth. Oncotarget 6, 34875\u201334891, https:\/\/doi.org\/10.18632\/oncotarget.5332 (2015).","journal-title":"Oncotarget"},{"key":"20268_CR59","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/hum.2006.17.379","volume":"17","author":"AR Yoon","year":"2006","unstructured":"Yoon, A. R. et al. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 17, 379\u2013390, https:\/\/doi.org\/10.1089\/hum.2006.17.379 (2006).","journal-title":"Hum Gene Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20268-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20268-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20268-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:00:10Z","timestamp":1671588010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20268-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["20268"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-20268-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"1 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2233"}}